The 'bufo' / Colorado River toad psychedelic (5-MeO-DMT, aka toad venom) — a short-acting tryptamine; GH Research's GH001 Phase 2b (2025) showed -15.5 MADRS vs placebo in TRD.
5-MeO-DMT is a tryptamine psychedelic structurally related to, but pharmacologically distinct from, the N,N-DMT found in ayahuasca. Unlike N,N-DMT, which is a relatively selective 5-HT2A agonist, 5-MeO-DMT is a non-selective serotonin agonist with particularly high affinity for the 5-HT1A receptor subtype — a different mechanism, and one researchers suspect underlies its distinct subjective profile.2
The compound occurs naturally in the venom of the Sonoran Desert toad (Incilius alvarius, formerly Bufo alvarius) and in several plant species. Most current clinical use relies on synthetic material; conservation and welfare concerns have pushed responsible practitioners away from toad-derived preparations.
The pharmacokinetics are what set 5-MeO-DMT apart:
The short duration is clinically attractive: a dose-and-discharge paradigm is feasible. In GH Research’s Phase 2b trial, 97.4% of patients were ready to be discharged within an hour of their last dose, with no post-discharge restrictions required.1
Published in JAMA Psychiatry in 2025, the GH001 TRD-201 trial (NCT05800860) is the most rigorous 5-MeO-DMT dataset to date.2
| Parameter | GH001 arm (n=40) | Placebo arm (n=41) |
|---|---|---|
| MADRS change from baseline, Day 8 | -15.2 points | +0.3 points |
| Placebo-adjusted difference | -15.5 points (p<0.0001) | |
| Remission at Day 8 (MADRS ≤10) | 57.5% | 0% |
| Response at Day 8 | 60.0% | 0% |
| Serious adverse events (double-blind period) | 0 | 0 |
The trial design used an individualized dosing regimen (IDR): up to three escalating doses (6 mg, 12 mg, 18 mg) on a single day, with psychological support but no planned psychotherapy — an important difference from psilocybin and MDMA protocols. This framing treats 5-MeO-DMT more like an anesthetic or a drug than a drug-plus-therapy intervention.
In the open-label extension phase, 73% of completers were in remission at 6 months, and most (63%) needed only 1–4 re-treatments to maintain that remission.2 Durability of this magnitude, with such infrequent dosing, is genuinely novel.
GH Research is not the only company chasing a 5-MeO-DMT drug. A second program, BPL-003, comes from AtaiBeckley — the company formed by the 2025 atai Life Sciences and Beckley Psytech merger. BPL-003 is an intranasal 5-MeO-DMT that also met its primary endpoint in a Phase 2b trial for treatment-resistant depression and holds FDA Breakthrough Therapy Designation. So the field now has two front-runners: GH001 (inhaled) and BPL-003 (intranasal), in what the press has framed as a race to build a “billion-dollar” depression treatment.
For a full head-to-head on the trial data, delivery methods, timelines, and the market thesis against Spravato, see our AtaiBeckley vs GH Research guide.
Most 5-MeO-DMT trials so far target depression, not PTSD. Interest in veterans is real, though: nonprofits such as The Mission Within have run psychedelic programs for veterans abroad, and short-acting compounds like 5-MeO-DMT are being watched for trauma-related conditions. For now, the formal evidence base is depression-focused, and any PTSD use remains investigational.
The Phase 2b trial reported:
5-MeO-DMT is Schedule I in the United States — possession and distribution carry felony penalties. Clinical research occurs under FDA Investigational New Drug (IND) authorization.
GH Research’s US development of GH001 was under FDA clinical hold for part of 2023–2025; the hold was lifted in early 2026, and the company has signaled a global Phase 3 program. If that program succeeds, GH001 would likely become the first 5-MeO-DMT product to face an NDA review.
Internationally, 5-MeO-DMT is scheduled in most countries but unscheduled in a few jurisdictions, where retreat-based access has emerged. Mexico and Costa Rica are the most common destinations for English-speaking retreat-goers. As with ayahuasca, regulatory frameworks in those countries are substantially lighter than the safeguards in clinical trials.
| Jurisdiction | Status |
|---|---|
| United States (federal) | Schedule I — no state or federal exemption. Oregon and Colorado's licensed psilocybin programs do not include 5-MeO-DMT. Colorado's Natural Medicine Health Act decriminalized possession of N,N-DMT specifically (the compound in ayahuasca) — that decriminalization does not extend to 5-MeO-DMT, which remains fully illegal under Colorado state law as well as federal law. |
| Mexico | Unregulated retreat access exists (see below) — not the same as a codified legal exemption; regulatory oversight is minimal. |
| Canada, UK, Netherlands, Germany, Portugal, Spain, Australia, India | No confirmed legal exemption for 5-MeO-DMT; it is controlled or scheduled in each of these jurisdictions the same way DMT and other Schedule I tryptamines are. |
Clinical trials. GH Research (NCT05800860 and planned Phase 3 successors), and a small number of academic studies — check ClinicalTrials.gov. Selection is competitive and most trials enroll treatment-resistant depression specifically.
International retreats. Safer operators publish their medical screening criteria, require medication disclosure, have medical staff on site, and do not combine 5-MeO-DMT with other psychedelics in a single session. Operators offering "toad medicine" as part of a longer multi-substance retreat carry meaningfully higher risk.
What to avoid. Any setting that does not ask about serotonergic medications, cardiovascular history, or personal/family psychosis history. Claims that 5-MeO-DMT treats depression, addiction, or trauma without clinical infrastructure. Combination with MAOIs, kambo, ayahuasca, or SSRIs in the same day. If a retreat pairs 5-MeO-DMT with kambo, read the kambo safety guide before booking.
Unlike psilocybin, MDMA, or ketamine protocols, the GH001 trial deliberately omitted structured psychotherapy — a signal that the drug’s benefit may not require the same preparation scaffolding. That said, ego-dissolution experiences of this magnitude typically require integration support afterward, particularly for people with trauma history. See the integration therapy guide.
No. 5-MeO-DMT is a Schedule I controlled substance under the federal Controlled Substances Act. It was specifically added to Schedule I in January 2011 (76 FR 238). Unlike N,N-DMT, 5-MeO-DMT is not covered by Colorado's Prop 122 decriminalization, which lists psilocybin, psilocin, DMT, ibogaine, and mescaline — but not 5-MeO-DMT. Possession or distribution carries federal felony penalties.
No. 5-MeO-DMT is Schedule I under both federal law and California Health & Safety Code. California's city-level entheogen deprioritization resolutions (Oakland, San Francisco, etc.) reference 'entheogenic plants and fungi' — 5-MeO-DMT from synthetic sources would not fall under that language, and these resolutions are not legal protections in any case.
5-MeO-DMT and N,N-DMT are chemically related but pharmacologically distinct. N,N-DMT primarily activates 5-HT2A receptors and produces a highly visual experience (often experienced as geometric patterns, entities, or alternate realities). 5-MeO-DMT primarily activates 5-HT1A receptors and produces a shorter, less visual, more all-encompassing ego-dissolution experience. Both are Schedule I, but only N,N-DMT is decriminalized in Colorado under Prop 122.
Get 5-MeO-DMT research & policy updates
New trials, FDA decisions, and legal changes for 5-MeO-DMT — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.